Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 8/20 | 0.62 |
| ▸ | SCN2A | Q99250 | 7/20 | 0.62 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30882106 | 1.00 | SCN10A (0.62) | SCN10ASCN2AMAPK8EPHX2RAF1 | |
| SCHEMBL23327910 | 0.88 | SCN10A (0.75) | SCN10ASCN2AMAPK8 | |
| SCHEMBL23327655 | 0.86 | SCN10A (0.68) | SCN10ASCN2AMAPK8 | |
| SCHEMBL23344751 | 0.84 | SCN10A (0.62) | SCN10ASCN2ATP53LMNATHRB | |
| SCHEMBL30882123 | 0.84 | SCN10A (0.68) | SCN10ASCN2AMAPK8 | |
| SCHEMBL23328017 | 0.84 | SCN10A (0.68) | SCN10ASCN2AMAPK8 | |
| SCHEMBL23327907 | 0.83 | SCN10A (0.66) | SCN10ASCN2A | |
| SCHEMBL23327999 | 0.80 | SCN10A (0.61) | SCN10ASCN2ATP53 | |
| SCHEMBL23344685 | 0.79 | SCN10A (0.60) | SCN10ASCN2A | |
| SCHEMBL30882103 | 0.78 | SCN10A (0.59) | SCN10ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | claimed |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | LIEBER INSTITUE, INC (US) | 2024-05-28 | — | — | US | claimed |
| CN-112689629-B | For inhibiting Nav1.8 Pyridazine Compounds | 利伯研究所公司 | 2024-04-23 | — | — | CN | claimed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | claimed |
| CN-112689629-A | For inhibiting Nav1.8 pyridazine Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | claimed |
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | LIEBER INSTITUE, INC (US) | 2024-05-28 | — | — | US | disclosed |
| CN-112689629-B | For inhibiting Nav1.8 Pyridazine Compounds | 利伯研究所公司 | 2024-04-23 | — | — | CN | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
| CN-112689629-A | For inhibiting Nav1.8 pyridazine Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | SCN10A 8/4885SCN2A 3/4885MAPK8 267/4885 |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | SCN8A, SCN5A, SCN2A | SCN10A 8/4885SCN2A 3/4885MAPK8 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.